PA8445301A1 - Inhibidores de metalproteasas-sulfamidas. - Google Patents

Inhibidores de metalproteasas-sulfamidas.

Info

Publication number
PA8445301A1
PA8445301A1 PA19988445301A PA8445301A PA8445301A1 PA 8445301 A1 PA8445301 A1 PA 8445301A1 PA 19988445301 A PA19988445301 A PA 19988445301A PA 8445301 A PA8445301 A PA 8445301A PA 8445301 A1 PA8445301 A1 PA 8445301A1
Authority
PA
Panama
Prior art keywords
amino
arilo
aralkyl
aryl
alkyl
Prior art date
Application number
PA19988445301A
Other languages
English (en)
Inventor
Chris Allen Broka
Jeffrey Allen Campbell
Arlindo Lucas Castelhano
Jian Jeffrey Chen
Robert Than Hendrick
Michael Joseph Melnick
Keith Adrian Murray Walker
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26713422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8445301(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PA8445301A1 publication Critical patent/PA8445301A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)

Abstract

LOS COMPUESTOS SELECCIONADOS DEL GRUPO DE COMPUESTOS REPRESENTADOS POR LA FORMULA (1): R1 Y R2 SON INDEPENDIENTEMENTE SELECCIONADOS DE HIDROGENO, ALQUILO, ALQUENILO, HALOALQUILO, CICLOALQUILO, CICLOALQUILALQUILO, ARILO, ARALQUILO, HETEROARILO, HETEROALQUILO, HETEROCICLO,HETEROCICLOALQUILO, O - (ALQUILENO)- C(O)-X DONDE X ES ALQUILO, HALOALQUILO, ALCOXILO, HALOALQUILOXILO,AMINO MONOSUBSTITUIDO O AMINO DISUBSTITUIDO, ARILO, ARALQUILO, ARILOXILO, HETEROARILOXILO, HIDROXILO, ARALQUILOXILO, HETEROARALQUILOXILO, O HETEROARILO O R1 Y R2 JUNTO CON EL ATOMO DE CARBONO AL CUAL ESTAN ENLAZADOS FORMAN UN CARBOCICLO O UN HETEROCICLO; R3 ES HIDROGENO, ALQUILO, ALQUENILO, HALOALQUILO, CICLOALQUILO, /CICLOALQUILALQUILO, ARILO, ARALQUILO, ARALQUENILO, HETEROARILO, HETEROARQUILO, HETEROCICLOALQUILO, HETEROALQUILO, O - (ALQUILENO)-C(O)-X DONDE X ES ALQUILO, HALOALQUILO, ALCOXILO, HALOALQUILOXILO, AMINO, AMINO MONOSUBSTITUIDO O AMINO DISUBSTITUIDO, ARILO, ARALQUILO, ARILOXILO, HETEROARILOXILO, HIDROXILO, ARALQUILOXILO, HETEROALQUILOXILO, O HETEROARILO; O R3 JUNTO CON CUALQUIERA R1 O R2 Y LOS ATOMOS A LOS CUALES ESTAN ENLAZADOS FORMAN UN GRUPO HETEROCICLOAMINO; R10 ES -NHOH O -OR11 DONDE R11 ES HIDROGENO, ALQUILO, O ACILO; R20 Y R21 SON INDEPENDIENTEMENTE SELECCIONADOS DE HIDROGENO, ALQUILO, HETEROALQUILO, CICLOALQUILO, CICLOALQUILALQUILO, ARILO, ARALQUILO, O HETEROARALQUILO,; Ò R20 Y R21 JUNTO CON EL ATOMO DE NITROGENO AL CUAL ESTAN UNIDOS FORMAN UN GRUPO HETEROCICLOAMINO; O CUALESQUIERA DE R20 Y R21 JUNTO CON R3 FORMAN UN GRUPO ALQUILENO; Y SUS SALES, PROFARMACOS, ISOMEROS INDIVIDUALES Y MEZCLAS DE ISOMEROS FARMACEUTICAMENTE ACEPTABLES SON INHIBIDORES DE METALOPROTEASAS, Y POR CONSIGUIENTE SON UTILES EN EL TRATAMIENTO DE ESTADOS DE ENFERMEDAD ALIVIADOS MEDIANTE LA INHIBICION DE DICHAS METALOPROTEASAS.
PA19988445301A 1997-01-23 1998-01-21 Inhibidores de metalproteasas-sulfamidas. PA8445301A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3671497P 1997-01-23 1997-01-23
US6220997P 1997-10-16 1997-10-16

Publications (1)

Publication Number Publication Date
PA8445301A1 true PA8445301A1 (es) 2001-07-31

Family

ID=26713422

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19988445301A PA8445301A1 (es) 1997-01-23 1998-01-21 Inhibidores de metalproteasas-sulfamidas.

Country Status (35)

Country Link
EP (1) EP0958287B2 (es)
JP (1) JP3563411B2 (es)
KR (1) KR100377696B1 (es)
CN (1) CN1093125C (es)
AR (1) AR011425A1 (es)
AT (1) ATE223909T1 (es)
AU (1) AU730127B2 (es)
BG (1) BG103586A (es)
BR (1) BR9807508A (es)
CA (1) CA2278694C (es)
DE (2) DE69807845T2 (es)
DK (1) DK0958287T3 (es)
EA (1) EA002810B1 (es)
ES (2) ES2183331T3 (es)
FR (1) FR2758559A1 (es)
GB (1) GB2321641B (es)
HR (1) HRP980036A2 (es)
HU (1) HUP0000941A3 (es)
ID (1) ID22849A (es)
IL (1) IL130802A0 (es)
IS (1) IS5125A (es)
IT (1) IT1298163B1 (es)
MA (1) MA26467A1 (es)
NO (1) NO313635B1 (es)
NZ (1) NZ336625A (es)
OA (1) OA11078A (es)
PA (1) PA8445301A1 (es)
PE (1) PE57399A1 (es)
PL (1) PL334846A1 (es)
PT (1) PT958287E (es)
TN (1) TNSN98012A1 (es)
TR (1) TR199901765T2 (es)
UY (1) UY24854A1 (es)
WO (1) WO1998032748A1 (es)
YU (1) YU34599A (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
HN2000000052A (es) * 1999-05-28 2001-02-02 Pfizer Prod Inc Hidroxiamidas de acidos 3- (arilsulfonilamino)- tetrahidrofuran-3-carboxilicos.
CA2374460A1 (en) 1999-06-04 2000-12-14 Astrazeneca Ab Inhibitors of metalloproteinases
TR200202211T2 (tr) * 1999-08-18 2002-11-21 Warner-Lambert Company Matris metaloproteinaz inhibitörleri olarak kullanışlı olan hidroksamik asit bileşikleri
DOP2000000107A (es) 1999-12-01 2002-09-16 Agouron Pharmaceutical Inc Compuestos, composiciones y metodos para estimular el crecimiento y alongamiento de las neuronas
WO2001062750A1 (en) * 2000-02-21 2001-08-30 Astrazeneca Ab Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
JP4256095B2 (ja) 2000-02-21 2009-04-22 アストラゼネカ・アクチエボラーグ メタロプロテイナーゼの阻害剤としてのピペリジン−およびピペラジン置換ｎ−ヒドロキシホルムアミド類
US6495358B1 (en) * 2000-04-19 2002-12-17 Wichita State University Sulfamide and bis-sulfamide amino acid derivatives as inhibitors of proteolytic enzymes
US6897237B2 (en) 2000-04-28 2005-05-24 Shionogi & Co. Ltd. MMP-12 inhibitors
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
US6492171B2 (en) 2000-05-16 2002-12-10 Isis Pharmaceuticals, Inc. Antisense modulation of TERT expression
GB0119474D0 (en) 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
JP4219810B2 (ja) * 2001-10-26 2009-02-04 塩野義製薬株式会社 Ｍｍｐ阻害作用を有するスルホンアミド誘導体
NZ536116A (en) * 2002-04-03 2007-01-26 Topotarget Uk Ltd Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
EP1511488B1 (en) * 2002-06-12 2013-05-22 Symphony Evolution, Inc. Human adam-10 inhibitors
EP1493445A1 (en) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
DE10344936A1 (de) * 2003-09-27 2005-04-21 Aventis Pharma Gmbh Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen
AU2005244450B2 (en) * 2004-05-19 2010-08-19 Solvay Pharmaceuticals Gmbh Medicaments containing N-sulfamoyl-N'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
JP5043668B2 (ja) * 2004-09-20 2012-10-10 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
DE102004060229A1 (de) 2004-12-15 2006-06-29 Sanofi-Aventis Deutschland Gmbh Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen
US20090069304A1 (en) 2006-03-03 2009-03-12 Shionogi & Co., Ltd. Mmp-13 selective inhibitor
WO2008053913A1 (fr) 2006-11-02 2008-05-08 Shionogi & Co., Ltd. Dérivé de sulfonylurée capable d'inhiber sélectivement mmp-13
WO2008147764A1 (en) * 2007-05-23 2008-12-04 Array Biopharma, Inc. Mmp inhibitors and methods of use thereof
AR068849A1 (es) 2007-10-12 2009-12-09 Basf Se Procedimiento para la preparacion de diamidas de acido sulfonico
FR2947268B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
ES2736200T3 (es) * 2009-07-22 2019-12-26 Univ Illinois Inhibidores de HDAC y métodos terapéuticos que utilizan los mismos
EP2718279B1 (en) * 2011-06-09 2016-08-10 Rhizen Pharmaceuticals SA Novel compounds as modulators of gpr-119
EP3297992B1 (en) * 2015-05-22 2020-02-05 Chong Kun Dang Pharmaceutical Corp. Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same
BR112021006407A8 (pt) 2018-10-04 2022-12-06 Inst Nat Sante Rech Med uso de inibidores do egfr para ceratodermas

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH617318A5 (en) † 1975-09-30 1980-05-30 Ciba Geigy Ag Microbicidal composition.
US5140009A (en) * 1988-02-10 1992-08-18 Tap Pharmaceuticals, Inc. Octapeptide LHRH antagonists
US5114937A (en) * 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
IE68045B1 (en) * 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
WO1993006127A1 (en) * 1991-09-17 1993-04-01 Warner-Lambert Company Novel amino acid prodrug renin inhibitors
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
NZ284812A (en) † 1994-05-04 1998-06-26 Novartis Ag N-sulphonyl and n-sulphinyl amino acid amides; microbicides
DE19507447A1 (de) † 1995-03-03 1996-09-05 Vitronic Dr Ing Stein Bildvera Verfahren und Schaltung zum Erfassen und Weiterleiten von Videobilddaten in einem PC
RU2164914C2 (ru) * 1995-11-13 2001-04-10 Хехст Акциенгезелльшафт ЦИКЛИЧЕСКИЕ И ГЕТЕРОЦИКЛИЧЕСКИЕ N-ЗАМЕЩЕННЫЕ α-ИМИНОГИДРОКСАМОВЫЕ И КАРБОНОВЫЕ КИСЛОТЫ
DK0780386T3 (da) * 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
FR2748026B1 (fr) * 1996-04-26 1998-06-05 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
BG103586A (bg) 2000-03-31
FR2758559A1 (fr) 1998-07-24
HRP980036A2 (en) 1998-12-31
WO1998032748A1 (en) 1998-07-30
DE69807845T2 (de) 2003-06-05
PE57399A1 (es) 1999-06-25
AU6614098A (en) 1998-08-18
MA26467A1 (fr) 2004-12-20
NO993587L (no) 1999-09-22
ID22849A (id) 1999-12-09
IT1298163B1 (it) 1999-12-20
EA002810B1 (ru) 2002-10-31
ES2183331T3 (es) 2003-03-16
IS5125A (is) 1999-07-22
EA199900643A1 (ru) 2000-04-24
AU730127B2 (en) 2001-02-22
BR9807508A (pt) 2000-03-21
CN1250445A (zh) 2000-04-12
CA2278694C (en) 2006-09-26
DK0958287T3 (da) 2003-01-20
YU34599A (sh) 2002-03-18
EP0958287B2 (en) 2008-04-09
DE69807845D1 (de) 2002-10-17
CA2278694A1 (en) 1998-07-30
CN1093125C (zh) 2002-10-23
PT958287E (pt) 2002-12-31
GB9801393D0 (en) 1998-03-18
AR011425A1 (es) 2000-08-16
UY24854A1 (es) 2000-12-29
OA11078A (en) 2003-03-17
KR20000070398A (ko) 2000-11-25
ATE223909T1 (de) 2002-09-15
HUP0000941A3 (en) 2002-06-28
DE19802350A1 (de) 1998-07-30
NO313635B1 (no) 2002-11-04
HUP0000941A2 (hu) 2001-04-28
TR199901765T2 (xx) 1999-10-21
JP3563411B2 (ja) 2004-09-08
GB2321641B (en) 2001-04-04
ES2136037B1 (es) 2000-11-16
JP2001523222A (ja) 2001-11-20
PL334846A1 (en) 2000-03-27
KR100377696B1 (ko) 2003-03-29
IL130802A0 (en) 2001-01-28
EP0958287B1 (en) 2002-09-11
EP0958287A1 (en) 1999-11-24
NO993587D0 (no) 1999-07-22
ES2136037A1 (es) 1999-11-01
ITMI980091A1 (it) 1999-07-20
GB2321641A (en) 1998-08-05
TNSN98012A1 (fr) 2005-03-15
NZ336625A (en) 2001-04-27

Similar Documents

Publication Publication Date Title
PA8445301A1 (es) Inhibidores de metalproteasas-sulfamidas.
CY1112130T1 (el) Ενεργοποιητης για υποδοχεα δελτα αποκρινομενος σε πολλαπλασιαστη υπεροξειδιοσωματος
DE69406649T2 (de) N-alkyl-2-substituierte atp-analoge
HUP0301607A2 (hu) Szelektív neurokinin antagonista hatású nitrogéntartalmú heterociklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
CO5700733A2 (es) Acidos aminocarboxilicos sustituidos
ES2189234T3 (es) Nuevos derivados de taxano.
AR041867A1 (es) Agente para prevenir o tratar neuropatia
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
CY1106858T1 (el) Νεα παραγωγα κυκλικου αμιδιου
CY1106674T1 (el) Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους
HUP0302955A2 (hu) HMG-CoA reduktáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk koleszterinnel kapcsolatos betegségek kezelésére
CY1108813T1 (el) Αναστολεις κινασων τυροσινης
ATE205213T1 (de) Pentacyclische verbindungen
DK0521787T3 (da) Vanadiumkomplekser, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
MX9701765A (es) Derivado heterociclico y medicina.
AR246289A1 (es) Composicion inhibidora de polimerizacion.
ES2052917T3 (es) Derivados de piperidina.
CO5550494A2 (es) Derivados de diamina, proceso para producir los derivados de diamina, y fungicidas que contienen los derivados de diamina como ingrediente activo
AR039172A1 (es) Derivados de morfolina, antagonistas de ccr3.
ES2133544T3 (es) Derivados de indazol.
PA8466101A1 (es) Agentes terapeuticos
CO4910142A1 (es) Compuestos de furano nitrona
HUP0000554A2 (hu) Eljárás N-szubsztituált 3-hidroxi-pirazolok előállítására
ES2172294T3 (es) Nuevos derivados del 1-indanol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
DE69219124D1 (de) Fungizide verbindungen